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Nilotinib is a new phenylaminopyrimidine with enhanced activity and selectivity against the Bcr-Abl tyrosine kinase compared with imatinib, and promises to improve upon the treatment of chronic myeloid leukaemia and imatinib-resistant disease. 1, 2 Imatinib is well-tolerated by most chronic myeloid leukaemia patients, with a 5-year overall survival rate in newly diagnosed disease of 89%, although it has been observed that some patients showed an association with altered bone and mineral metabolism. 3 This effect is suggested to be caused by a reduction in osteoclast activity, perhaps due to the inhibition of platelet derived growth factor (PDGF) or receptor for MCSF (FMS) receptors by imatinib. 3 Figure 1a shows that nilotinib, like imatinib, 4 inhibited the proliferation of FDC-P1 cells expressing normal human FMS (FD-c-fms) in response to macrophage colony stimulating factor (M-CSF). The concentration of nilotinib at which 50% inhibition of growth occurred (cellular IC 50 ) was calculated from Figure 1a as 0.3 mM. As expected, FDc-fms cells stimulated to grow by interleukin-3 (IL-3) instead of M-CSF were not inhibited by nilotinib. The D802V mutant FMS receptor is oncogenic and so can stimulate the growth of FDC-P1 cells in the absence of either IL-3 or M-CSF. The D802V mutation, which corresponds to D816V of KIT, confers complete resistance to imatinib, 4 and similarly, as shown in Figure 1a , this mutation conferred marked but not complete resistance to nilotinib.
The oncogenic V-Fms receptor is not resistant to imatinib, and Figures 1b and c show that the transformed morphology that is characteristic of rodent fibroblasts that express V-Fms 4,5 is suppressed by nilotinib. Phalloidin staining of actin (Figures 1d and e) shows that nilotinib suppressed membrane ruffling. Figure 1f shows that M-CSF addition caused phosphorylation of the mature form of human FMS expressed by Rat-2 fibroblasts (compare lanes 1 and 2), and that pretreatment with 250 or 500 nM nilotinib largely inhibited this process. The major phosphorylated band in Figure 1f is the mature FMS receptor and the higher molecular weight smearing is due to receptor ubiquitination. 4 Figure 1g shows that the phosphorylation of FMS D802VY708F, which is a more stable derivative of FMS D802V that is better suited to biochemical analysis, 6 was not substantially inhibited by nilotinib. Similarly, FMS D802VY708 also exhibited greater resistance to nilotinib than FMS in an in vitro kinase assay (Figure 1h ). The oncogenic D802V mutation causes phosphorylation of both the immature and mature receptor forms, and this occurs constitutively in the absence of M-CSF (Figure 1g) . 4 As expected, nilotinib inhibited the phosphorylation of MAPK and Akt in Rat-2 c-fms fibroblasts in response to M-CSF (Supplementary Figure S1) .
We next assessed the inhibitory effect of nilotinib upon osteoclastogenesis of human mononuclear progenitor cells mobilized from bone marrow. Figure 2a shows a representative photograph of human osteoclasts, which have multiple nuclei and a distinctive actin ring. Progenitor cells were grown in 96-well trays in triplicate with M-CSF and RANKL and the indicated concentrations of nilotinib ( Figure 2b ). After 2 weeks the cells were stained for TRAP and TRAP-positive osteoclasts with three or more nuclei were counted. Figure 2b shows that nilotinib inhibited osteoclastogenesis with an IC 50 value of 50 nM; similar IC 50 values were obtained in two further experiments. By contrast, in the same experiments imatinib had an IC 50 value of 600 nM for the inhibition of osteoclastogenesis, which is in accord with a previous report. 7 Figure 2c illustrates that pit formation by osteoclasts grown on dentine slices was inhibited by nilotinib or imatinib, as expected. Imatinib can induce the apoptosis of mature osteoclasts 8 and Figure 2d shows that nilotinib has a similar effect at concentrations in the 500-1000 nM range. Figure 2e shows that imatinib and nilotinib had similar inhibitory profiles of macrophage colony formation by murine bone marrow mononuclear (BMM) in response to M-CSF.
Figure 2f models the docking of nilotinib into the recently determined structure of the inactive kinase domain of FMS. 9 The predicted binding pose of nilotinib in the FMS active site is supported by the fact that it predicts four hydrogen-bond interactions between nilotinib and the kinase domain of FMS that are analogous to those observed in the co-crystal structure of imatinib and KIT. 10 These predicted interactions are mediated by residues that are conserved between these two members of the type III receptor tyrosine kinase family. 9, 10 Overall, the cellular and biochemical IC 50 values of nilotinib and imatinib for FMS inhibition were similar, as has been reported for PDGFR-a and -b. 11 Consequently, the 420-fold increase in inhibition of Bcr-Abl by nilotinib compared with imatinib, represents significantly greater selectivity for the former drug towards Bcr-Abl. Nilotinib and imatinib had similar profiles of inhibition of macrophage colony growth from murine bone marrow, 12, 13 although nilotinib more potently inhibited human osteoclast formation. The induction of apoptosis of mature osteoclasts by nilotinib occurred at concentrations (500-1000 nM) that are consistent with inhibition of FMS (Figure 2d) . However, the relatively low IC 50 value of 50 nM for the inhibition of osteoclast formation by nilotinib suggests a target other than FMS.
A number of studies have demonstrated that imatinib and other FMS kinase inhibitors can inhibit osteoclast function in primary cultures and in animals, 7, 8, [14] [15] [16] which supports the suggestion that osteoclast and osteoblast function might be affected in those patients who show evidence of altered bone metabolism following treatment with imatinib. 3 In accordance with this, the plasma trough levels of imatinib and nilotinib that are normally achieved in patients 2 are greater than the IC 50 values that we observed for osteoclast inhibition ex vivo. However, it should be noted that our observed inhibition of osteoclastogenesis ex vivo occurs at drug concentrations much higher than those required to inhibit Bcr-Abl activity.
There is great interest in the therapeutic potential of FMS kinase inhibitors due to the critical role of FMS signalling in the production and function of macrophages, osteoclasts and microglial cells. Enhanced activity of these cell types, which are derived from a common progenitor stem cell pool during haematopoiesis, is implicated in a wide range of diseases, which include macrophage-mediated inflammatory disease and cancer metastasis; osteoporosis, osteolytic bone destruction in cancer and microglial-mediated neurological diseases. 14, [17] [18] [19] Inhibition of osteoclast or macrophage activity significantly reduces bone metastasis in a number of mouse models of this disease. 14, 17, 19 Imatinib alleviates arthritis in rodent models of this disease and consequently shows promise for patient treatment. 7 It may well be important to develop a range of inhibitors against FMS in order that the wide spectrum of potential therapeutic applications of such drugs can be fully evaluated. 18 The discovery that imatinib and nilotinib can inhibit FMS, together with the available structural information 9,10 provides a strong platform for the rational development of clinically valuable FMS inhibitors. 
